Betamethasone/calcipotriol - Novartis

Drug Profile

Betamethasone/calcipotriol - Novartis

Alternative Names: BFH 772; Calcipotriol/betamethasone - Novartis

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Corticosteroids; Cyclohexanes; Dihydroxycholecalciferols; Fluorinated steroids; Indenes; Pregnadienetriols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Psoriasis; Rosacea

Most Recent Events

  • 29 Feb 2012 Novartis completes a phase II trial in Rosacea in USA (NCT01449591)
  • 30 Sep 2011 Phase-II clinical trials in Rosacea in USA (Topical)
  • 27 Apr 2010 Novartis completes a phase I/II trial in Psoriasis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top